Trastuzumab biosimilar - Biocon/Mylan

Drug Profile

Trastuzumab biosimilar - Biocon/Mylan

Alternative Names: Bmab-200; CANMAb; Hercules; HerMyl 1401O trastuzumab; Hertraz; MYL 1401O; Ogivri; trastuzumab-dkst

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocon
  • Developer Biocon; Mylan
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Registered Gastric cancer

Most Recent Events

  • 01 Dec 2017 Registered for Breast cancer in USA (IV)
  • 01 Dec 2017 Registered for Gastric cancer (Metastatic disease) in USA (IV)
  • 01 Dec 2017 Trastuzumab biosimilar has boxed warning for the increased risk of Cardiomyopathy, Infusion reactions, Embryo-foetal toxicities and Pulmonary toxicity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top